Ironwood Pharmaceuticals | IRWD - Interest Expense On Debt


Ironwood Pharmaceuticals reported $8.74M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Agios Pharmaceuticals USD 1.39B 85.53M Sep/2025
Akebia Therapeutics 364.15M 18.56M Sep/2025
Alnylam Pharmaceuticals USD 129.34M 84.94M Dec/2025
Amarin USD 3K 5K Dec/2024
Ardelyx USD 5.8M 784K Sep/2025
Astellas Pharma JPY 3.91B 320M Mar/2025
AstraZeneca USD 484M 181M Dec/2025
Charles River Laboratories USD 23.78M 1.63M Dec/2025
Coherus Biosciences USD 2.15M 3.2M Mar/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Exact Sciences USD 9.79M 46K Sep/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Incyte USD 582K 10K Dec/2025
Ironwood Pharmaceuticals USD 8.74M 506K Dec/2024
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Moderna USD 12.14B 12.13B Sep/2025
Myriad Genetics USD 800K 100K Mar/2025
Pacira USD 3.89M 387K Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Puma Biotechnology USD 3.37M 11K Jun/2024
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Takeda JPY 123.63B 40.49B Dec/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
Vanda Pharmaceuticals 601.14M 23.61M Sep/2025